Metabolism of paclitaxel in mice

被引:16
作者
Bardelmeijer, HA [1 ]
Oomen, IAM [1 ]
Hillebrand, MJX [1 ]
Beijnen, JH [1 ]
Schellens, JHM [1 ]
van Tellingen, O [1 ]
机构
[1] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Dept Clin Chem, NL-1066 CX Amsterdam, Netherlands
关键词
high-performance liquid chromatography; mass spectrometry; metabolism; mice; paclitaxel;
D O I
10.1097/00001813-200303000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous mass balance studies in humans and mice have shown that the fecal and urinary recovery of paclitaxel and known metabolites (3'p-hydroxypaclitaxel, 6alpha-hydroxypaclitaxel and 3'p,6alpha-dihydroxypaclitaxel) was not complete. Obviously this discrepancy is caused by the existence of other yet unknown metabolites. Mdr1a/1b(-/-) mice excrete very low quantities of unchanged paclitaxel. We have therefore used these mice receiving i.v. [H-3]paclitaxel to further study the metabolic fate of paclitaxel. The major part of the radiolabel, being 70%, was excreted in the feces. A lipophilic sample, containing about 70% of the radioactivity present in the feces sample, was obtained by diethyl ether extraction. The aqueous residue containing about 30% of the radioactivity was further extracted using methanol. The high-performance liquid chromatography (HPLC) chromatograms of the lipophilic and aqueous sample revealed two and five putative new metabolites of paclitaxel, respectively. The HPLC fractions containing substantial amounts of radioactivity were subjected to tandem mass spectrometry. Two novel monohydroxylated paclitaxel structures were identified, which are probably 2m-hydroxypaclitaxel and 19-hydroxypaclitaxel, structures previously identified in rats. Including these metabolites, about 60% of the mass balance of paclitaxel could be quantified.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 21 条
[1]  
ANDERSON CD, 1995, DRUG METAB DISPOS, V23, P1286
[2]  
CRESTEIL T, 1994, CANCER RES, V54, P386
[3]   Human liver microsomal metabolism of paclitaxel and drug interactions [J].
Desai, PB ;
Duan, JZ ;
Zhu, YW ;
Kouzi, S .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (03) :417-424
[4]  
HARRIS JW, 1994, CANCER RES, V54, P4026
[5]   TAXANES - A NEW CLASS OF ANTITUMOR AGENTS [J].
HUIZING, MT ;
MISSER, VHS ;
PIETERS, RC ;
HUININK, WWT ;
VEENHOF, CHN ;
VERMORKEN, JB ;
PINEDO, HM ;
BEIJNEN, JH .
CANCER INVESTIGATION, 1995, 13 (04) :381-404
[6]  
JamisDow CA, 1995, CANCER CHEMOTH PHARM, V36, P107
[7]  
KLECKER RW, 1994, DRUG METAB DISPOS, V22, P254
[8]  
KUMAR GN, 1994, J PHARMACOL EXP THER, V268, P1160
[9]   Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration [J].
Malingré, MM ;
Schellens, JHM ;
van Tellingen, O ;
Rosing, H ;
Koopman, FJ ;
Duchin, K ;
Huinink, WWT ;
Swart, M ;
Beijnen, JH .
ANTI-CANCER DRUGS, 2000, 11 (10) :813-820
[10]  
Monsarrat B, 1993, J Natl Cancer Inst Monogr, P39